Get the Stockscreener App
68.65
3.49%
2.45
Halozyme Therapeutics Inc stock is traded at $68.65, with a volume of 960.26K.
It is up +3.49% in the last 24 hours and down -0.68% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$66.20
Open:
$67.64
24h Volume:
960.26K
Relative Volume:
0.47
Market Cap:
$8.05B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
22.73
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+4.76%
1M Performance:
-0.68%
6M Performance:
+11.96%
1Y Performance:
+17.17%
1-Day Range:
$65.00
$69.93
1-Week Range:
$63.84
$69.93
52-Week Range:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.83 | 7.74B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.78 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.49 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.43 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.67 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.44 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - Zacks Investment Research
HALO Receives Maintained Rating and Raised Price Target by Citiz - GuruFocus
Citizens raises Halozyme Therapeutics stock price target to $92 on strong royalty growth - Investing.com Nigeria
Hussman Strategic Advisors Inc. Grows Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics: Q3 Earnings Snapshot - New Haven Register
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliableWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - newser.com
Halozyme Rides Strong Royalty Growth To Lift Its Outlook - Finimize
Halozyme Q3 2025 slides: royalty revenue surges 52%, guidance raised on strong growth By Investing.com - Investing.com South Africa
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insi - GuruFocus
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insight - GuruFocus
Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... - Yahoo Finance
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Halozyme Q3 2025 slides: royalty revenue surges 52%, guidance raised on strong growth - Investing.com Nigeria
Why Halozyme Therapeutics Inc. stock is in analyst buy zoneDividend Hike & Stepwise Swing Trade Plans - newser.com
Halozyme Therapeutics (HALO) Reports Record Q3 Revenue Growth - GuruFocus
Transcript : Halozyme Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Halozyme (HALO) Q3 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Halozyme Q3 2025 beats earnings expectations - Investing.com
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates - Yahoo! Finance Australia
HALO Boosts 2025 Revenue Forecast Amid Strong Earnings Outlook - GuruFocus
Halozyme Raises 2025 Guidance After Strong Q3 Results - TipRanks
Halozyme Therapeutics, Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS - PR Newswire
Can Halozyme Therapeutics Inc. stock continue upward trendJuly 2025 Market Mood & Risk Managed Investment Strategies - newser.com
What insider trading reveals about Halozyme Therapeutics Inc. stockTrade Entry Report & Entry Point Strategy Guides - newser.com
Strategies to average down on Halozyme Therapeutics Inc.Market Trend Report & Verified Stock Trade Ideas - newser.com
Tools to assess Halozyme Therapeutics Inc.’s risk profileJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Exit strategy if you’re trapped in Halozyme Therapeutics Inc.Exit Point & AI Powered Buy/Sell Recommendations - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersPortfolio Update Summary & Stepwise Swing Trade Plans - newser.com
Torray Investment Partners LLC Has $2.08 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarBreakout Watch & AI Based Buy/Sell Signal Reports - newser.com
Why Halozyme Therapeutics Inc. stock could be next big winner2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Assetmark Inc. Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arkadios Wealth Advisors Acquires 11,457 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingIPO Watch & Risk Managed Investment Strategies - newser.com
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Halozyme Therapeutics (HALO) Anticipates Strong Q3 Earnings Grow - GuruFocus
Will Halozyme Therapeutics Inc. stock see PE expansionMarket Activity Report & High Accuracy Investment Signals - newser.com
Combining price and volume data for Halozyme Therapeutics Inc.2025 Price Targets & Low Risk Entry Point Tips - newser.com
Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
AlphaQuest LLC Purchases 5,133 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALOZYME THERAPEUTICS Earnings Preview: Recent $HALO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
1.68%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):